This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Oscar H. Del Brutto, MD
Guayaquil, Ecuador

Arch Intern Med. 1997;157(1):128-129.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

It is with great surprise that I read the article on anticysticercal drug therapy by Carpio et al.¹ In that study, anticysticercal drugs were not better than symptomatic therapy for the resolution of parenchymal brain cysticerci and did not modify the clinical course of the disease. These results differ from those reported in most studies about praziquantel or albendazole therapy for parenchymal neurocysticercosis (NC)^2-10 and did not match with those previously reported by the same authors in the same population of patients with NC. In 1988, Carpio et al¹¹ described 20 patients with parenchymal NC in whom albendazole was highly effective and caused a 84% reduction in the number of brain cysts. Because albendazole has been used to treat human NC since 1986,³ it must be assumed that those 20 patients had to be included in their 1995 study, because, according to the authors, "Between July . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?